

Name: Ryan M. Gill, MD, PhD
Position: Professor (Clinical X series for Clinician Scholars)
 Director of Surgical Pathology
 Department of Pathology

EDUCATION

| | | | |
|-------------|---|---------------------------|-----------------------------------|
| 1995 - 1999 | Colorado State University, Fort Collins, CO | B.S. | Magna Cum Laude, Microbiology |
| 1999 - 2003 | University of Kansas, Kansas City, KS | Ph.D. | Pathology |
| 1999 - 2005 | University of Kansas, Kansas City, KS | M.D. | |
| 2005 - 2009 | University of California, San Francisco | Resident / Chief Resident | Pathology & Laboratory Medicine |
| 2009 - 2010 | University of California, San Francisco | Fellow | Hematopathology |
| 2010 - 2011 | University of California, San Francisco | Fellow | Gastrointestinal/ Liver Pathology |

LICENSES, CERTIFICATION

- 2006 Medical licensure, California
- 2009 Board Certification, Anatomic & Clinical Pathology, American Board of Pathology
- 2010 Board Certification, Hematology, American Board of Pathology
- 2019 10-year Continuing Certification cycle completion for both Anatomic & Clinical Pathology and Hematology, American Board of Pathology

PRINCIPAL POSITIONS HELD

| | | | |
|-------------|--|---|-----------|
| 2011 - 2011 | HS Clinical Instructor of Pathology. | University of California, San Francisco, CA | Pathology |
| 2011 - 2014 | Assistant Professor (Clinical X series). | University of California, San Francisco, CA | Pathology |
| 2014 - 2018 | Associate Professor (Clinical X series). | University of California, San Francisco, CA | Pathology |

Prepared: December 1, 2020

2018 - present Professor (Clinical X series).

University of
California, San
Francisco, CA

Pathology

OTHER POSITIONS HELD CONCURRENTLY

1999 - 2005 University of Kansas, Kansas City, KS

M.D./Ph.D. student
Physician
Scientist
Training
Program

2005 - 2010 University of California, San Francisco

Fellow
Molecular
Medicine
Training
Program

2011 - 2014 University of California, San Francisco

Associate Director
of Residency
Program
Pathology

2014 - 2017 University of California, San Francisco

Associate Director
of Surgical
Pathology
Pathology

2017 - present UCSF Medical Center at Parnassus, Anatomic
Pathology Laboratories

Medical Director
Pathology

2017 - present University of California, San Francisco

Director of Surgical
Pathology
Pathology

HONORS AND AWARDS

1999 Physician Scientist Training Program
Scholar

University of Kansas (KUMC)

2000 Summer Research Fellow

American Academy of Allergy, Asthma, and
Immunology (AAAAI)

2002 Frontiers in Reproductive Biology Attendee
Marine Biological Laboratory (Woods Hole,
MA)

2003 Merit Award

American Society for Investigative
Pathology

2004 Alpha Omega Alpha (AOA)

Medical Honor Society (elected as a junior
medical student, Kansas Chapter)

2006 Resident Research Award

University of California, San Francisco
(UCSF), Department of Laboratory
Medicine

2008 Russell J. Eilers Scholar

American Pathology Foundation

2008 Chief Resident

UCSF Department of Pathology, San
Francisco General Hospital

| | | |
|------|---------------------------------|--|
| 2009 | Chief Resident | UCSF Department of Laboratory Medicine |
| 2009 | Visiting Hematopathology Fellow | NIH (Laboratory of Pathology, Hematopathology section), 1 month. |
| 2017 | Elected Member | The International Liver Pathology Study Group (ELVES) |

MEMBERSHIPS

- 2002 - 2005 American Society for Investigative Pathology
- 2005 - present United States and Canadian Academy of Pathology
- 2006 - present College of American Pathologists
- 2008 - 2017 American Pathology Foundation
- 2010 - present Hans Popper Hepatopathology Society
- 2012 - present Rodger Haggitt Gastrointestinal Pathology Society
- 2013 - 2014 South Bay Pathology Society
- 2016 - 2017 Association of Directors of Anatomic and Surgical Pathology, Associate Member
- 2017 - present Association of Directors of Anatomic and Surgical Pathology, Regular Member
- 2017 - present Pancreatobiliary Pathology Society
- 2017 - present The International Liver Pathology Study Group (ELVES)

SERVICE TO PROFESSIONAL ORGANIZATIONS

- 2005 - 2006 College of American Pathologists Inspector
- 2009 - 2012 American Pathology Foundation Finance Committee
- 2010 - 2012 United States and Canadian Academy of Pathology (USCAP) Resident Advisory Committee
- 2012 - 2015 United States and Canadian Academy of Pathology (USCAP) Membership Committee
- 2012 - 2017 American Pathology Foundation Board of Directors
- 2013 - 2016 United States and Canadian Academy of Pathology (USCAP) GI section abstract reviewer
- 2015 - 2015 United States and Canadian Academy of Pathology (USCAP) Interactive Microscopy Session, Meet the Experts (GI)
- 2015 - present NIH NASH Clinical Research Network P&P committee selected reviewer
- 2016 - 2016 United States and Canadian Academy of Pathology (USCAP) Liver platform session, moderator

- 2016 - 2019 United States and Canadian Academy of Pathology (USCAP) GI section leader, assigns platform presentations
- 2019 - 2019 United States and Canadian Academy of Pathology (USCAP) Interactive Microscopy Course (GI)
- 2021 - 2021 United States and Canadian Academy of Pathology (USCAP) Interactive Microscopy Course (GI&Liver)

SERVICE TO PROFESSIONAL PUBLICATIONS

- 2013 - 2019 Modern Pathology (USCAP abstract reviewer- GI)
- 2014 - present Journal of Cutaneous Pathology, Editor: Dr. Tim McCalmont, (Ad hoc reviewer)
- 2016 - present Virchows Archive, Editor: Dr. Volkan Adsay, (Ad hoc reviewer)
- 2016 - present Modern Pathology: Dr. John Eble, (Ad hoc reviewer)
- 2016 - present Hepatology: Dr. Rohit Loomba/Dr. David Cohen, (Ad hoc reviewer)
- 2016 - present Human Pathology, Case Reports: Dr. Jagdish Butany (Ad hoc reviewer)
- 2016 - present Clinics and Practice: Dr. Paola Granata (Ad hoc reviewer)
- 2018 - present Blood: Dr. Georgia Vogelsang (Ad hoc reviewer)
- 2019 - present Hepatology Communications: Dr. Norah Terrault (Ad hoc reviewer)
- 2020 - present JAMA Network Open: Dr. Frederick P. Rivara (Ad hoc reviewer)

INTERNATIONAL INVITED PRESENTATIONS

- 2009 U.S. and Canadian Academy of Pathology, Annual Meeting, Boston, MA, March 2009 (two posters)
- 2010 U.S. and Canadian Academy of Pathology, Annual Meeting, Washington, DC, March 2010 (platform presentation)
- 2012 U.S. and Canadian Academy of Pathology, Annual Meeting, Vancouver, Canada, March 2012 (two poster presentations)
- 2013 U.S. and Canadian Academy of Pathology, Annual Meeting, Baltimore, MD, March 2013 (two posters)
- 2014 U.S. and Canadian Academy of Pathology, Annual Meeting, San Diego, CA, March 2014 (one poster, evening specialty conference invited speaker)
- 2015 U.S. and Canadian Academy of Pathology, Annual Meeting, Boston, MA, March 2015 (three posters, Interactive Microscopy, Meet the Experts, course faculty-GI)
- 2016 U.S. and Canadian Academy of Pathology, Annual Meeting, Seattle, WA, March 2016 (three posters)

- 2017 Hans Popper Hepatopathology Society, U.S. and Canadian Academy of Pathology, Annual Meeting, San Antonio, TX, March 2017 (invited speaker)
- 2017 U.S. and Canadian Academy of Pathology, Annual Meeting, San Antonio, TX, March 2017 (three posters)
- 2017 29th European Congress of Pathology, Amsterdam RAI, The Netherlands, September 2017 (invited speaker)
- 2017 Australian Gastrointestinal Pathology Society, Annual National Meeting, Brisbane, Australia, October 2017 (invited speaker, hosted by Dr. Ian Brown)
- 2017 Royal North Shore Hospital Liver Pathology Meeting, Sydney, Australia, October 2017 (Invited Speaker, hosted by Drs. Ian Brown and Anthony Gill)
- 2017 Dorevitch Pathology Education Session, Melbourne, Australia, October 2017 (Invited Speaker, hosted by Drs. Ian Brown and Robyn Laurie)
- 2018 U.S. and Canadian Academy of Pathology, Annual Meeting, Vancouver, Canada, March 2018 (5 posters)
- 2018 The International Liver Pathology Study Group (ELVES) Annual Meeting, Bordeaux, France, October 2018 (invited presentation)
- 2019 U.S. and Canadian Academy of Pathology, Interactive Microscopy Course: Twists and Turns of Problematic GI Pathology and How to Find Your Way Out! Course Director: Gregory Lauwers, M.D.; Palm Springs, CA (2 sessions)
- 2019 U.S. and Canadian Academy of Pathology, Annual Meeting, Washington DC, March 2019 (5 posters)
- 2019 The International Liver Pathology Study Group (ELVES) Annual Meeting, New York, NY, November 2019 (invited presentation)
- 2020 U.S. and Canadian Academy of Pathology, Annual Meeting, Los Angeles, CA, March 2020 (1 poster)
- 2021 U.S. and Canadian Academy of Pathology, Interactive Microscopy Course: GI & Liver Pathology. Course Director: Deepa Patil, M.D.; Palm Springs, CA (2 sessions)
- 2021 The International Liver Pathology Study Group (ELVES) Annual Meeting, Lausanne, Switzerland, delayed, originally planned for October 2020 (invited presentation)
- 2021 U.S. and Canadian Academy of Pathology, Annual Meeting, remote presentation, March 2021 (evening Liver specialty conference invited speaker)

NATIONAL INVITED PRESENTATIONS

- 2001 NIH 16th annual national M.D./Ph.D. student meeting, Aspen, CO, 2001 (one poster)
- 2002 Society for Gynecologic Investigation, Annual Meeting, Los Angeles, CA, 2002 (platform presentation)
- 2003 Experimental Biology, Chugai Symposium for Young Investigators, 2003 (platform presentation)
- 2003 Frontiers in Reproduction, Annual Symposium, Woods Hole, MA, 2003 (one poster)
- 2007 Frontiers in Reproduction, Annual Symposium, Woods Hole, MA, 2007 (platform presentation)
- 2007 College of American Pathologists, Annual Meeting, Chicago, IL, 2007 (one poster)
- 2008 KUMC Annual M.D./Ph.D. Student Retreat (invited lecture)
- 2012 Liver Pathology Companion Meeting, American Society of Clinical Pathology (ASCP), Hynes Convention Center, Boston, MA (invited lecture)
- 2015 UCSF Department of Pathology Symposium for Dr. Linda Ferrell (Organizer, Moderator, and Speaker)
- 2016 University of Kansas, Department of Pathology Grand Rounds, Kansas City, KS (invited lecture)
- 2016 University of Kansas, Department of Pathology Unknown Conference, Kansas City, KS (invited lecture)
- 2018 31st Annual Park City Anatomic Pathology Update, The Lodges at Deer Valley, Park City, UT (invited lecture)

REGIONAL AND OTHER INVITED PRESENTATIONS

- 2005 KUMC perinatal grand rounds, Kansas City, KS (lecture)
- 2005 UCSF Mechanisms of Disease Conference, Department of Pathology, San Francisco, CA (lecture)
- 2006 UCSF Mechanisms of Disease Conference, Department. of Pathology, San Francisco, CA (lecture)
- 2006 Blood Systems Research Institute (BSRI) Microchimerism Symposium, San Francisco, CA (platform presentation)
- 2006 UCSF Mechanisms of Disease Conference, Department. of Pathology, San Francisco, CA (lecture)
- 2007 UCSF Mechanisms of Disease Conference, Department. of Pathology, San Francisco, CA (lecture)

- 2007 UCSF Mechanisms of Disease Conference, Department. of Pathology, San Francisco, CA (lecture)
- 2008 UCSF Mechanisms of Disease Conference, Department. of Pathology, San Francisco, CA (lecture)
- 2008 South Bay Pathology Society, Palo Alto, CA (case presentation)
- 2008 UCSF Mechanisms of Disease Conference, Department. of Pathology, San Francisco, CA (lecture)
- 2009 UCSF Mechanisms of Disease Conference, Department. of Pathology, San Francisco, CA (lecture)
- 2009 UCSF Mechanisms of Disease Conference, Department. of Pathology, San Francisco, CA (lecture)
- 2009 NIH/NCI Department of Pathology, Division of Hematopathology, Bethesda, MD (lecture)
- 2009 Genzyme CLL education conference (hosted by Dr. Tom Martin), San Francisco, CA (lecture)
- 2009 UCSF Hematology/Oncology Grand Rounds, San Francisco, CA (lecture)
- 2010 UCSF Hematology/Oncology Interesting Case Presentation, San Francisco, CA (lecture))
- 2012 15th Annual UCSF Current Issues in Anatomic Pathology, Hotel Nikko, San Francisco, CA (invited speaker)
- 2013 16th Annual UCSF Current Issues in Anatomic Pathology, Hotel Nikko, San Francisco, CA (invited speaker)
- 2013 Internal Medicine, Gastroenterology, IBD, Four Seasons, San Francisco, CA (invited panelist)
- 2014 17th Annual UCSF Current Issues in Anatomic Pathology, Hotel Nikko, San Francisco, CA (invited speaker)
- 2014 Internal Medicine, Gastroenterology, IBD, St. Regis Hotel, San Francisco, CA (invited panelist)
- 2015 Internal Medicine, Gastroenterology, IBD, St. Regis Hotel, San Francisco, CA (invited panelist/speaker)
- 2015 18th Annual UCSF Current Issues in Anatomic Pathology, Hotel Nikko, San Francisco, CA (invited speaker)
- 2016 Internal Medicine, Gastroenterology, IBD, St. Regis Hotel, San Francisco, CA (invited panelist/speaker)
- 2016 Nathan Bass UCSF Liver Transplant Conference, Silverado Resort, Napa, CA (invited speaker)
- 2016 19th Annual UCSF Current Issues in Anatomic Pathology, Hotel Nikko, San Francisco, CA (invited speaker)

- 2017 20th Annual UCSF Current Issues in Anatomic Pathology, Hotel Nikko, San Francisco, CA (invited speaker)
- 2017 UCSF Department of Pathology Research Symposium, Cavallo Point, Sausalito, CA (invited speaker)
- 2018 21st Annual UCSF Current Issues in Anatomic Pathology, Hotel Nikko, San Francisco, CA (invited speaker)
- 2018 Internal Medicine, Gastroenterology, IBD, St. Regis Hotel, San Francisco, CA (invited panelist/speaker)
- 2018 Nathan Bass UCSF Liver Transplant Conference, Silverado Resort, Napa, CA (invited speaker)
- 2019 22nd Annual UCSF Current Issues in Anatomic Pathology, Intercontinental Hotel, San Francisco, CA (invited speaker)
- 2019 Nathan Bass UCSF Liver Transplant Conference, Silverado Resort, Napa, CA (invited speaker)
- 2020 Internal Medicine, UCSF Gastroenterology, IBD, online (invited panelist/speaker)

RESEARCH AWARDS - CURRENT

| | | | |
|---|-----------------|----------------------|-----------------------------|
| 1. U01 DK61738 NIH/NIDDK NIH/NIDDK NASH CRN | Co-Investigator | 08/01/2014 | Terrault (PI) 06/30/2024 |
| | | \$ 261,194 direct/yr | \$ 2,952,926 total |
| | | 1 | |

This long standing grant established the non-alcoholic steatohepatitis (NASH) clinical research network (CRN), a multi-institution collaboration to study the clinicopathologic features and natural history of NASH in the United States.

PEER REVIEWED PUBLICATIONS

1. Gill RM, Ni J, Hunt JS. Differential Expression of LIGHT and Its Receptors in Human Placentas and Amniochorion Membranes. American Journal of Pathology, 161(6) 2011-2017, 2002.
2. Gill RM, Ka H, Hunt JS. TRAIL, LIGHT, and the Expanding Tumor Necrosis Factor Superfamily in Human Placentas. PINSAs, B69(2) 41-53, 2003.
3. Gill RM, Hunt JS. Soluble Receptor (DcR3) and Cellular Inhibitor of Apoptosis-2 (cIAP-2) Protect Human Cytotrophoblast Cells Against LIGHT-Mediated Apoptosis. American Journal of Pathology, 165(1) 309-317, 2004.
4. Gill RM, Coleman N, Hunt JS. Differential Cellular Expression of LIGHT and Its Receptors in Early Gestation Human Placentas. Journal of Reproductive Immunology, 74(1-2) 1-6, 2007.
5. Gill RM, Etzell J. Basophilic Leukemia in Recurrent Chronic Myelogenous Leukemia Blast Phase, American Journal of Hematology, 82(8) 736-737, 2007.

6. **Gill RM**, Lee TH, Utter GH, Reed WF, Wen L, Chafets D, Busch MP. The TNF (-308A) Polymorphism Is Associated with Microchimerism in Transfused Trauma Patients. *Blood*, 111(7) 3880-3883, 2008.
7. **Gill RM**, Karlson W, Ezzell J. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Clinical and Pathological Features. ASCP check sample program, Hematology H08-4(H-319). 43(4) 49-70, 2008.
8. **Gill RM**, O'Donnell R, Horvai A. Utility of Immunohistochemistry for Endothelial Markers in Distinguishing Epithelioid Hemangioendothelioma from Carcinoma Metastatic to Bone. *Archives of Pathology and Laboratory Medicine*, 133 967-972, 2009.
9. Hunt JS, Pace JL, **Gill RM**. Immunoregulatory Molecules in Human Placentas: Potential for Diverse Roles in Pregnancy. *International Journal of Developmental Biology*, 54(2-3):457-467, 2010.
10. **Gill RM**, Ferrell LD. Vanishing Bile Duct Syndrome Associated with Peripheral T-Cell Lymphoma, Not Otherwise Specified, Arising in a Post-Transplant Setting. *Hepatology*, 51(5):1856-1857, 2010.
11. **Gill RM**, Belt P, Wilson L, Bass NM, Ferrell LD. Centrizonal Arteries and Microvessels in Non-Alcoholic Steatohepatitis. *American Journal of Surgical Pathology*. 35(9):1400-4, 2011.
12. Van Loon K, **Gill RM**, McMahon P, Chigurupati R, Siddiqi I, Fox L, Damon L, McCalmont TH, Jordan R, Wolf J. 20q- Clonality in a Case of Oral Sweet's Syndrome and Myelodysplasia. *American Journal of Clinical Pathology*. 137(2):310-5, 2012.
13. Can NT, Robertson P, Zaloudek CJ, **Gill RM**. Cervical Squamous Cell Carcinoma Metastatic to Placenta. *International Journal of Gynecologic Pathology*, 32(5):516-9, 2013.
14. **Gill RM** and Kakar S. Non-Alcoholic Steatohepatitis: An Update on Diagnostic Challenges. *Surgical Pathology Clinics*, 6(2):227-257, 2013.
15. Buelow, B., Lambert J., **Gill RM**. Fusobacterium Liver Abscess. *Case Reports in Gastroenterology*. 2013, 7(3):482-6.
16. St-Jules DE, Watters CA, Brunt EM, Wilkens LR, Novotny R, Belt P, Lavine JE; **Nonalcoholic Steatohepatitis Clinical Research Network**. Estimation of fish and ω -3 fatty acid intake in pediatric nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr*. 2013 Nov;57(5):627-33. *Gill RM is listed as a NASH CRN collaborator*
17. Miracle AC, Behr SC, Benhamida J, **Gill RM**, Yeh BC. Mesenteric Inflammatory Venous-Occlusive Disease: Radiographic and Histopathologic Evaluation of 2 Cases. *Abdominal Imaging*, 2014, 39(1):18-24.
18. Siddique A, Nelson JE, Aouizerat B, Yeh MM, Kowdley KV; **NASH Clinical Research Network**. Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin. *Clin Gastroenterol Hepatol*. 2014 Jul;12(7):1170-8. *Gill RM is listed as a NASH CRN collaborator*
19. Schwimmer JB, Zepeda A, Newton KP, Xanthakos SA, Behling C, Hallinan EK, Donithan M, Tonascia J; **Nonalcoholic Steatohepatitis Clinical Research Network**. Longitudinal assessment of high blood pressure in children with nonalcoholic/> fatty liver disease. *PLoS One*. 2014 Nov 24;9(11):e112569. *Gill RM is listed as a NASH CRN collaborator*
20. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarthy S, Diehl AM, Hameed B, Kowdley KV, McCullough A, Terrault N, Clark

- JM, Tonascia J, Brunt EM, Kleiner DE, Doo E; **NASH Clinical Research Network**. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. *Lancet*. 2015 Mar 14;385(9972):956-65. *Gill RM is listed as a NASH CRN collaborator*
21. Corey KE, Vuppalanchi R, Wilson LA, Cummings OW, Chalasani N; **NASH CRN**. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels. *Aliment Pharmacol Ther*. 2015, 41(3):301-9. *Gill RM is listed as a NASH CRN collaborator*
 22. Yeh MM, Belt P, Brunt EM, Kowdley KV, Wilson LA, Ferrell L; **Nonalcoholic Steatohepatitis Clinical Research Network**. Acidophil Bodies in Nonalcoholic Steatohepatitis. *Hum Pathol*. 2016 Feb 1. pii: S0046-8177(16)00033-2. *Gill RM is listed as a NASH CRN collaborator*
 23. Cho SJ, Ferrell LD, **Gill RM**. Expression of liver fatty acid binding protein in hepatocellular carcinoma. *Human Pathology*. 2016, 50, 135-139
 24. Klair JS, Yang JD, Abdelmalek MF, Guy CD, **Gill RM**, Yates K, Unalp-Adrida A, Lavine J, Clark J, Diehl AM, Suzuki A; for NASH CRN. A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease. *Hepatology*. 2016, 64(1), 85-91
 25. **Gill RM**, Buelow B, Mather C, Joseph NM, Alves, V, Brunt EM, Liu T, Makhlof H, Marginean C, Nalbantoglu I, Sempoux C, Snover DC, Thung SN, Yeh MM, Ferrell LD. Hepatic Small Vessel Neoplasm, a Rare Infiltrative Vascular Neoplasm of Uncertain Malignant Potential. *Human Pathology*. 2016, 54, 143-151
 26. Choi W., Chang T., **Gill RM**. Gastrointestinal Zygomycosis Masquerading as Acute Appendicitis. *Case Reports in Gastroenterology*. 2016, 10 (1):81-87
 27. Tsokos C, Krings G, Yilmaz F, Ferrell LD, **Gill RM**. Proliferative Index Facilitates Distinction Between Benign Biliary Lesions and Intrahepatic Cholangiocarcinoma. *Human Pathology*, 2016, 57, 61-67
 28. Yang JD, Abdelmalek MF, Guy CD, **Gill RM**, Lavine JE, Yates K, Klair J, Terrault NA, Clark JM, Unalp-Arida A, Diehl AM, Suzuki A; NASH CRN. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol*, 2016, Aug 11, epub ahead of print
 29. Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, **Gill R**, Loomba R, Diehl AM, Aouizerat B; NASH Clinical Research Network. Novel Plasma Biomarkers Associated with Liver Disease Severity in Adults with Nonalcoholic Fatty Liver Disease. *Hepatology*. 2016 Aug 17. doi: 10.1002/hep.28776. [Epub ahead of print]/> PubMed PMID: 27532276.
 30. Hale G, Liu X, Hu J, Xu Z, Che L, Solomon D, Tsokos C, Shafizadeh N, Chen X, **Gill R**, Kakar S. Correlation of exon 3 β -catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma. *Mod Pathol*. 2016 Jul 29. doi: 10.1038/modpathol.2016.122. [Epub ahead of print] PubMed PMID: 27469330.
 31. Nelson JE, Handa P, Aouizerat B, Wilson L, Vemulakonda LA, Yeh MM, Kowdley KV; **NASH Clinical Research Network**. Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. *Aliment Pharmacol Ther*. 2016 Oct 11. *Gill RM is listed as a NASH CRN collaborator*
 32. Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, Barlow SE, Vos MB, Karpen SJ, Molleston JP, Whitington PF, Rosenthal P, Jain AK, Murray KF, Brunt

- EM, Kleiner DE, Van Natta ML, Clark JM, Tonascia J, Doo E; **NASH CRN**. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. *Gastroenterology*. 2016 Dec;151(6):1141-1154.e9. *Gill RM is listed as a NASH CRN collaborator*
33. Giard JM, Decker KA, Lai JC, **Gill RM**, Logan AC, Fix OK. Acute Liver Failure Secondary to Hemophagocytic Lymphohistiocytosis during Pregnancy. *ACG Case Rep J*. 2016 Nov 23;3(4):e162.
34. Choi WT, Jen KY, Wang D, Tavakol M, Roberts JP, **Gill RM**. Donor Liver Small Droplet Macrovesicular Steatosis is Associated with Increased Risk for Recipient Allograft Rejection. *American Journal of Surgical Pathology*, 2017, Jan 4. doi: 10.1097/PAS.0000000000000802.
35. Bean GR, Joseph NM, **Gill RM**, Folpe AL, Horvai AE, Umetsu SE. Recurrent *GNAQ* mutations in anastomosing hemangiomas. *Mod Pathol*. 2017 Jan 13. doi: 10.1038/modpathol.2016.234.
36. Geha R, Peters M, **Gill RM**, Dhaliwal G. Histology Rings True. *N Engl J Med*. 2017 Mar 2;376(9):869-874. doi: 10.1056/NEJMcps1609391. PubMed PMID: 28249146.
37. Tsai JH, Ferrell LD, Tan V, Yeh MM, Sarkar M, **Gill RM**. Aggressive non-alcoholic steatohepatitis following rapid weight loss and/or malnutrition. *Mod Pathol*. 2017 Mar 3. doi: 10.1038/modpathol.2017.13. [Epub ahead of print] PubMed PMID: 28256569.
38. Chen B, Wei W, Ma L, Yang B, **Gill RM**, Chua MS, Butte AJ, So S. Computational Discovery of Niclosamide Ethanolamine, A Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells in Vitro and in Mice by Inhibiting CDC37 Signaling. *Gastroenterology*. 2017 Mar 8. pii: S0016-5085(17)30264-0. doi: 10.1053/j.gastro.2017.02.039. [Epub ahead of print] PubMed PMID: 28284560.
39. Newton KP, Feldman HS, Chambers CD, Wilson L, Behling C, Clark JM, Molleston JP, Chalasani N, Sanyal AJ, Fishbein MH, Lavine JE, Schwimmer JB; **Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)**. Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. *J Pediatr*. 2017 Mar 30. pii: S0022-3476(17)30356-6. doi: 10.1016/j.jpeds.2017.03.007. [Epub ahead of print] PubMed PMID: 28366357. *Gill RM listed as a NASH CRN collaborator*
40. Africa JA, Behling CA, Brunt EM, Zhang N, Luo Y, Wells A, Hou J, Belt PH, Kohil R, Lavine JE, Molleston JP, Newton KP, Whittington PF, Schwimmer JB; **Nonalcoholic Steatohepatitis Clinical Research Network**. In Children With Nonalcoholic Fatty Liver Disease, Zone 1 Steatosis Is Associated With Advanced Fibrosis. *Clin Gastroenterol Hepatol*. 2017 Mar 7. pii: S1542-3565(17)30261-6. doi: 10.1016/j.cgh.2017.02.030. [Epub ahead of print] PubMed PMID: 28286193. *Gill RM listed as a NASH CRN collaborator*
41. Perito ER, Ajmera V, Bass NM, Rosenthal P, Lavine JE, Schwimmer JB, Yates KP, Diehl AM, Molleston JP, Murray KF, Scheimann A, **Gill R**, Glidden D, Aouizerat, B for the NASH Clinical Research Network. Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease. *Hepatology Communications*. 2017, 1(7), 609-622. PubMed PMID: 29130075
42. Wen KW, **Gill RM**. Immature Terminal Deoxynucleotidyl Transferase Positive B Cells are Detected in a Subset of Adult and Pediatric Liver Biopsies. *Appl Immunohistochem Mol Morphol*. 2017 Sep 29. doi: 10.1097/PAI.0000000000000596. [Epub ahead of print] PubMed PMID: 28968264.

43. Graham RP, Yeh MM, Lam-Himlin D, Roberts LR, Terracciano L, Cruise MW, Greipp PT, Zreik RT, Jain D, Zaid N, Salaria SN, Jin L, Wang X, Rustin JG, Kerr SE, Sukov WR, Solomon DA, Kakar S, Waterhouse E, **Gill RM**, Ferrell L, Alves VA, Nart D, Yilmaz F, Roessler S, Longerich T, Schirmacher P, Torbenson MS. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. *Mod Pathol*. 2017 Sep 1. doi: 10.1038/modpathol.2017.103. [Epub ahead of print] PubMed PMID: 28862261.
44. Mukhopadhyay S, Feldman MD, Abels E, Ashfaq R, Beltaifa S, Cacciabeve NG, Cathro HP, Cheng L, Cooper K, Dickey GE, **Gill RM**, Heaton RP Jr, Kerstens R, Lindberg GM, Malhotra RK, Mandell JW, Manlucu ED, Mills AM, Mills SE, Moskaluk CA, Nelis M, Patil DT, Przybycin CG, Reynolds JP, Rubin BP, Saboorian MH, Salicru M, Samols MA, Sturgis CD, Turner KO, Wick MR, Yoon JY, Zhao P, Taylor CR. Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology: A Multicenter Blinded Randomized Noninferiority Study of 1992 Cases (Pivotal Study). *Am J Surg Pathol*. 2017 Sep 28. doi: 10.1097/PAS.0000000000000948. [Epub ahead of print] PubMed PMID: 28961557.
45. Fernandez A, Conrad M, **Gill RM**, Choi WT, Kumar V, Behr S. Solitary fibrous tumor in the abdomen and pelvis: A case series with radiological findings and treatment recommendations. *Clin Imaging*. 2017 Oct 7;48:48-54. doi: 10.1016/j.clinimag.2017.10.002. [Epub ahead of print] PubMed PMID: 29028514.
46. Kushner T, Shinkai K, Fox L, Ying D, Gross A, Balitzer D, **Gill R**, Brandman D. New Presentation of Autoimmune Hepatitis with Erythema Multiforme. *Hepatology*. 2017 Oct 23. doi: 10.1002/hep.29610. [Epub ahead of print] PubMed PMID: 29059460.
47. Choi WT, Brown I, Ushiku T, Yozu M, Setia N, Srivastava A, Johncilla M, Pai RK, **Gill RM**, Fukayama M, Misdraji J, Lauwers GY. Gastric Pyloric Gland Adenoma: A Multicenter Clinicopathologic Study of 67 Cases. *Histopathology*. 2018 May;72(6):1007-1014. doi: 10.1111/his.13460. Epub 2018 Mar 5
48. Hameed B, Terrault NA, **Gill RM**, Loomba R, Chalasani N, Hoofnagle JH, Van Natta ML; NASH CRN. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. *Aliment Pharmacol Ther*. 2018 Jan 14. doi: 10.1111/apt.14492.
49. Ajmera V, Belt P, Wilson LA, **Gill RM**, Loomba R, Kleiner DE, Neuschwander-Tetri BA, Terrault N; NASH Clinical Research Network. Among Patients with Nonalcoholic Fatty Liver Disease, Modest Alcohol Use is Associated with Less Improvement in Histologic Steatosis and Steatohepatitis. *Clin Gastroenterol Hepatol*. 2018 Jan 25. pii: S1542-3565(18)30094-6. doi: 10.1016/j.cgh.2018.01.026. [Epub ahead of print] PubMed PMID: 29378307.
50. Roberts DE, Kakar S, Mehta N, **Gill RM**. A point-based histologic scoring system for hepatocellular carcinoma can stratify risk of post-transplant tumor recurrence. *American Journal of Surgical Pathology*. 2018, Apr 11. doi: 10.1097/PAS.0000000000001053.
51. Choi WT and **Gill RM**. Hepatic lymphoma diagnosis. *Surgical Pathology Clinics*. 2018. published online ahead of print: <https://doi.org/10.1016/j.path.2018.02.003>
52. Harlow KE, Africa JA, Wells A, Belt PH, Behling CA, Jain AK, Molleston JP, Newton KP, Rosenthal P, Vos MB, Xanthakos SA, Lavine JE, Schwimmer JB; **Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)**. Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. *J Pediatr*. 2018 Apr 13. pii: S0022-3476(18)30281-6. doi: 10.1016/j.jpeds.2018.02.038. [Epub ahead of print] PubMed PMID: 29661561. ***Gill RM** listed as a NASH CRN collaborator*

53. Joseph NM, Brunt E, Marginean EC, Nalbantoglu I, Thung S, Yeh MM, Umetsu SE, Ferrell LD, Snover DC, and **Gill RM**. Frequent *GNAQ* and *GNA14* mutations in hepatic small vessel neoplasm. *American Journal of Surgical Pathology*. 2018, July 3 doi: 10.1097/PAS.0000000000001110. [Epub ahead of print]
54. Choi WT, Wen KW, Rabinovitch PS, Huang D, Mattis AN, **Gill RM**. DNA Content Analysis of Colorectal Serrated Lesions Detects an Aneuploid Subset of Inflammatory Bowel Disease-Associated Serrated Epithelial Change and Traditional Serrated Adenomas. *Histopathology*. 2018 May 17. doi: 10.1111/his.13652. [Epub/> ahead of print] PubMed PMID: 29772067.
55. Kumar P, **Gill RM**, Phelps A, et al. (April 24, 2018) Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives. *Cureus* 10(4): e2527. DOI 10.7759/cureus.2527
56. van Leeuwen DJ, Alves V, Balabaud C, Bhathal PS, Bioulac-Sage P, Colombari R, Crawford JM, Dhillon AP, Ferrell L, **Gill R**, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Emmanuel Rautou P, Sempoux C, Snover DC, Theise ND, Thung SN, Tsui WMS, and Quaglia A. Acute-on-chronic liver failure (ACLF) 2018: A need for (urgent) liver biopsy? *Expert Rev Gastroenterol Hepatol*. 2018 Jun;12(6):565-573.
57. Guido M, Alves VA, Balabaud C, Bathal PS, Bioulac-Sage P, Colombari R, Crawford JM, Dhillon AP, Ferrell LD, **Gill RM**, Hytiroglou P, Nakanuma Y, Paradis V, Quaglia A, Rautou PE, Theise ND, Thung S, Tsui WM, Sempoux C, Snover D, van Leuwen DJ; INTERNATIONAL LIVER PATHOLOGY STUDY GROUP. Histology of portal vascular changes associated with idiopathic non-cirrhotic portal hypertension: nomenclature and definition. *Histopathology*. 2018 Aug 21. doi: 10.1111/his.13738. [Epub ahead of print] Review. PubMed PMID: 30129657.
58. Banini BA, Cazanave SC, Yates KP, Asgharpour A, Vincent R, Mirshahi F, Le P, Contos MJ, Tonascia J, Chalasani NP, Kowdley KV, McCullough AJ, Behling CA, Schwimmer JB, Lavine JE, Sanyal AJ; **Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)**. Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis. *J Clin Gastroenterol*. 2018 Dec 21. doi: 10.1097/MCG.0000000000001142. [Epub ahead of print] PubMed PMID: 30586008. *Gill RM listed as a NASH CRN collaborator*
59. Siddiqui MS, Yamada G, Vuppalanchi R, Van Natta M, Loomba R, Guy C, Brandman D, Tonascia J, Chalasani N, Neuschwander-Tetri B, Sanyal AJ; **NASH Clinical Research Network**. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. *Clin Gastroenterol Hepatol*. 2019 Aug;17(9):1877-1885.e5. doi: 10.1016/j.cgh.2018.12.031. Epub 2019 Jan 4. PubMed PMID: 30616027; PubMed Central PMCID: PMC6609497. *Gill RM listed as a NASH CRN collaborator*
60. Hammami MB, **Gill R**, Thiruvengadam N, Oh DY, Beck K, Mahadevan U, Kattah MG. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin. *Dig Dis Sci*. 2019 Mar;64(3):685-688. doi: 10.1007/s10620-019-05534-5. PubMed PMID: 30778872.
61. Wen KW, Umetsu SE, Goldblum JR, **Gill RM**, Kim GE, Joseph, NM, Rabinovitch, PS, Kakar, S, Lauwers GY, and Choi, W. DNA Flow Cytometric and Interobserver Study of “Crypt Cell Atypia” in Inflammatory Bowel Disease. *Histopathology*, 2019 May 20. doi: 10.1111/his.13923. [Epub ahead of print] PubMed PMID: 31111543.
62. McMahon M, Contreras A, Holm M, Uechi T, Forester CM, Pang X, Jackson C, Calvert ME, Chen B, Quigley DA, Luk JM, Kelley RK, Gordan JD, **Gill RM**, Blanchard SC, Ruggero D. A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS.

- Elife. 2019 Sep 3;8. pii: e48847. doi: 10.7554/eLife.48847. [Epub ahead of print] PubMed PMID: 31478838.
63. Kleiner DE, Brunt EM, Wilson LA, Behling C, Guy C, Contos M, Cummings O, Yeh M, **Gill R**, Chalasani N, Neuschwander-Tetri BA, Diehl AM, Dasarathy S, Terrault N, Kowdley K, Loomba R, Belt P, Tonascia J, Lavine JE, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. *JAMA Netw Open*. 2019 Oct 2;2(10):e1912565. doi: 10.1001/jamanetworkopen.2019.12565. PubMed PMID: 31584681.
 64. Sarkar M, Terrault N, Chan W, Cedars M, Huddleston H, Duwaerts CC, Balitzer D, **Gill RM**. Polycystic Ovary Syndrome (PCOS) Is Associated With NASH Severity and Advanced Fibrosis. *Liver Int*. 2019 Oct 18. doi: 10.1111/liv.14279. [Epub ahead of print] PubMed PMID: 31627243.
 65. Gawrieh S, Guo X, Tan J, Lauzon M, Taylor KD, Loomba R, Cummings OW, Pillai S, Bhatnagar P, Kowdley KV, Yates K, Wilson LA, Chen YI, Rotter JI, Chalasani N; **NASH Clinical Research Network**. A Pilot Genome-Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. *Hepatology Commun*. 2019 Nov 3;3(12):1571-1584. doi: 10.1002/hep4.1439. eCollection 2019 Dec. PubMed PMID: 31832568; PubMed Central PMCID: PMC6887685. *Gill RM listed as a NASH CRN collaborator*
 66. Sarkar M, Yates K, Suzuki A, Lavine J, **Gill R**, Ziegler T, Terrault N, Dhindsa S. Low Testosterone Is Associated With Nonalcoholic Steatohepatitis (NASH) and Severity of NASH Fibrosis in Men With NAFLD. *Clin Gastroenterol Hepatol*. 2019 Dec 5. pii: S1542-3565(19)31393-X. doi: 10.1016/j.cgh.2019.11.053. [Epub ahead of print] PubMed PMID: 31812658.
 67. Newton, K. P., Lavine, J. E., Wilson, L., Behling, C., Vos, M. B., Molleston, J. P., Rosenthal, P., Miloh, T., Fishbein, M. H., Jain, A. K., Murray, K. F., Schwimmer, J. B., & **Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)** (2020). Alanine Aminotransferase and Gamma Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis. *Hepatology (Baltimore, Md.)*, 10.1002/hep.31317. Advance online publication. <https://doi.org/10.1002/hep.31317> *Gill RM listed as a NASH CRN collaborator*
 68. Fels Elliott DR, Tavakol M, Lucas CH, Sheahon K, Kakar D, Hameed B, Ferrell LD, **Gill RM**. Clinicopathologic features and outcomes of parenchymal rejection in liver transplant biopsies [published online ahead of print, 2020 Jan 1]. *Histopathology*. 2020;10.1111/his.14058. doi:10.1111/his.14058
 69. Wen KW, Fakhri B, Menke J, Ruiz-Cordero R, **Gill RM**, Ohgami RS. Complexities in the diagnosis of large B-cell lymphomas, classic Hodgkin lymphomas and overlapping peripheral T-cell lymphomas simplified: An evidence-based guide. *Ann Diagn Pathol*. 2020;46:151534.
 70. Wu, C. H., Yang, C. Y., Wang, L., Gao, H. X., Rakhshandehroo, T., Afghani, S., Pincus, L., Balassanian, R., Rubenstein, J., **Gill, R.**, Bandyopadhyay, S., McCormick, F., Moasser, M., & Ai, W. Z. (2020). Cutaneous T cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3K α/δ and HDAC. *The Journal of investigative dermatology*, S0022-202X(20)31724-3. Advance online publication. <https://doi.org/10.1016/j.jid.2020.05.110/>> Format:
 71. Lee M, Ko HM, Rubino A, Lee H, **Gill R**, Lagana SM. Malakoplakia of the gastrointestinal tract: clinicopathologic analysis of 23 cases. *Diagn Pathol*. 2020;15(1):97. Published 2020 Jul 24. doi:10.1186/s13000-020-01013-y

72. Sarkar M, Suzuki A, Abdelmalek M, Yates K, Wilson L, Bass NM, **Gill R**, Cedars M, Terrault N; NASH Clinical Research Network (NASH CRN). Testosterone is Associated With Nonalcoholic Steatohepatitis (NASH) and Fibrosis in Pre-Menopausal Women With NAFLD. *Clin Gastroenterol Hepatol*. 2020 Sep 30:S1542-3565(20)31375-6. doi: 10.1016/j.cgh.2020.09.045. Epub ahead of print. PMID: 33010412.
73. Xanthakos SA, Lavine JE, Yates KP, Schwimmer JB, Molleston JP, Rosenthal P, Murray KF, Vos MB, Jain AK, Scheimann AO, Miloh T, Fishbein M, Behling CA, Brunt EM, Sanyal AJ, Tonascia J; **NASH Clinical Research Network**. Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. *Gastroenterology*. 2020 Nov;159(5):1731-1751.e10. doi: 10.1053/j.gastro.2020.07.034. Epub 2020 Jul 23. PMID: 32712103; PMCID: PMC7680281. *Gill RM listed as a NASH CRN collaborator*
74. Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C, Lavine J, Van Natta M, Middleton M, Tonascia J, Sirlin C; **NASH Clinical Research Network**. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. *Hepatology*. 2020 Jan 21. doi: 10.1002/hep.31121. Epub ahead of print. PMID: 31965579. *Gill RM listed as a NASH CRN collaborator*
75. **Gill, RM** and Theise, ND. Hering, Mall, and Rappaport, the Champions of Liver Microanatomy; Microscopic and Ultramicroscopic Anatomy of the Liver into the Modern Age. *Clinical Liver Disease*. In press

BOOKS AND CHAPTERS

1. **Gill RM**, Kakar S, Ferrell L. 18. Macrophage infiltrate. (2011) in Ferrell LD and Kakar S. *Liver Pathology*, 265-274, Demos Medical Publishing, New York, NY.
2. **Gill RM**, Pittaluga S, Siddiqi I. Myeloid Sarcoma (2012), In *Case Studies in Hematology and Coagulation*. ASCP, 446, 476.
3. **Gill RM**. Pittaluga S. Castleman Disease, Hyaline Vascular Variant (2012), In *Case Studies in Hematology and Coagulation*. ASCP, 277-279.
4. **Gill RM**. Bone and Joint Vascular Lesions (2012). in Horvai, A., *Bone and Soft Tissue Pathology*, 158, Elsevier, Philadelphia, PA.
5. **Gill RM**. Soft Tissue Vascular Tumors (2012), in Horvai, A., *Bone and Soft Tissue Pathology*, 372-403, Elsevier, Philadelphia, PA.
6. **Gill RM** and Kakar S. Chapter 36: Non-Neoplastic Liver Disease (2015), in S.E. Mills. *Sternberg's Diagnostic Surgical Pathology*, 6th edition, 1663-1703, Wolters Kluwer, Philadelphia, PA.
7. Ferrell LD, **Gill RM**, and Geisinger KR., Neoplasms and Tumor-Like Conditions of the Liver (2015), in Wick M, Livolsi V, Pfeifer J, Stelow E, Wakely P (eds). *Silverberg's Principles and Practice of Surgical Pathology and Cytopathology*, 5th edition, 2109-2144, Cambridge University Press, Cambridge, UK.
8. **Gill RM**, Pittaluga S, Siddiqi I. Myeloid Sarcoma (2019), In *Case Studies in Hematology and Coagulation*, second edition. ASCP, 446, 476.
9. **Gill RM**. Pittaluga S. Castleman Disease, Hyaline Vascular Variant (2019), In *Case Studies in Hematology and Coagulation*, second edition. ASCP, 277-279.

10. **Gill RM** and Kakar S. Chapter 18: Liver and Gallbladder (2020), in Kumar V, Abbas A, Aster J (eds). Robbins and Cotran Pathologic Basis of Disease, 10th edition, 823-880, Elsevier, Philadelphia, PA.
11. Ohgami R and **Gill RM**. Chapter. Lymphoma of the GI tract (2021). Practical Gastrointestinal Pathology: Frequently Asked Questions, Springer, edited by Drs. Hanlin Wang and Zongming Chen; *in press*.
12. **Gill RM** and Kakar S. Chapter 36: Non-Neoplastic Liver Disease (2021), in S.E. Mills. Sternberg's Diagnostic Surgical Pathology, 7th edition, Wolters Kluwer, Philadelphia, PA. *in press*

CONFERENCE ABSTRACTS

1. **Gill RM**, Ni J, Hunt JS. Localization of the TNF Superfamily Member, LIGHT, and Its TNFR Superfamily Member Receptors: HVEM, LTbR, and DcR3/TR6, in the Human Placenta. Journal of the Society for Gynecologic Investigation, 9(1), Supplement, 74A-75A, 2002.
2. Hunt JS, Phillips TA, Ka H, **Gill RM**. The TNF Supergene Family: Potential Functions in Human Placentas. Biology of Reproduction, 66, Supplement 1, 87, 2002.
3. **Gill RM**, Hunt JS. Human Placental Cytotrophoblast Cells: Resistance and Susceptibility to Killing by LIGHT and Interferon-g. FASEB, 17(4) A669, 2003.
4. **Gill RM**, Lee TH, Busch MP. The TNF (-308A) Polymorphism Is Associated with Microchimerism in Transfused Trauma Patients. Archives of Pathology and Laboratory Medicine, 131 (9) 1478, 2007.
5. **Gill RM**, O'Donnell RJ, Horvai AE. EGFR Expression, Amplification, and Kinase Domain Mutations Are Rare in Epithelioid Vascular Neoplasms. Modern Pathology, 22, supplement 1, 42A. 2009.
6. **Gill RM**, Brachtel EF, Horvai AE, Chen YY, Rabban JT. Immunoexpression of Fli-1 by Metaplastic Breast Cancer: A Potential Pitfall in Cases Morphologically Resembling Epithelioid Angiosarcoma, Modern Pathology, 22, supplement 1, 14A, 2009.
7. **Gill RM**, Bass NM, Ferrell LD. Characterization of CD34 Expression in Non-Alcoholic Steatohepatitis. Modern Pathology, 23, supplement 1, 355A, 2010
8. **Gill RM**, Alves V, Makhlof H, Sempoux C, Thung S, Ferrell LD. Small Vessel Hepatic Hemangioma, an Atypical Hemangioma Variant in Adult Liver. Modern Pathology, 25, supplement 2, 413A, 2012.
9. Krings G, Ferrell LD, **Gill RM**. Ki-67 and p53 Expression as an Immunohistochemical Tool in the Differential Diagnosis of Benign and Malignant Biliary Lesions. Modern Pathology, 25, supplement 2, 416A, 2012.
10. Cho SJ, Ferrell LD, **Gill RM**. Expression of Liver Fatty Acid Binding Protein (LFABP) in Hepatocellular Carcinomas. Modern Pathology, 26, supplement 2, 399A, 2013.
11. **Gill RM**, Sempoux C, Makhlof H, Thung S, Amancio TT, Alves V, and Ferrell LD. GLUT1 Expression in Adult Hepatic Vascular Neoplasms. Modern Pathology, 26, supplement 2, 402A, 2013.
12. Ng S., Haemel A., **Gill RM**, LeBoit P., Mahadevan U. Refractory Colitis with Skin Manifestations. American Journal of Gastroenterology. 2013.

13. Liu A, **Gill RM**. CD5-Positive Primary Cardiac Diffuse Large B-Cell Lymphoma: A Case Study. *American Journal of Clinical Pathology* August 2013, 140(suppl 1):A226-A226
14. Buelow B. and **Gill RM**. Morphologic Features to Distinguish Early Chronic Rejection from Recurrent Hepatitis C in Liver Allografts. *Modern Pathology*, 27, supplement 2, 417A, 2014.
15. Hiniker A, **Gill RM**, Christine C, Nussbaum R. Evaluation of Lewy Pathology in Enteric Neurons from Living Patients. *Journal of Neuropathology and Experimental Neurology*, May 2014, 73
16. Yang JD, Abdelmalek MF, Guy CD, **Gill RM**, Yates K, Unalp A, Lavine J, Diehl AM, Suzuki A. Associations of Sex and Menopause with Histologic Severity of Necroinflammation and Portal Inflammation Among Patients with Nonalcoholic Fatty Liver Disease (NAFLD). *Gastroenterology*, 2014 May,146(5): S-945.
17. Klair JS, Young JF, Abdelmalek MF, Guy CD, **Gill RM**, Yates K, Unalp A, Lavine J, Clark J, Diehl AM, Suzuki A. Risk of Severe Fibrosis with Age at Menopause in Nonalcoholic Fatty Liver Disease (NAFLD). 2014, *Hepatology*, 60, S1, 621A.
18. Buelow B, Ferrell LD, **Gill RM**. C-MYC Over-Expression Is Rare in Hepatic Small Vessel Hemangioma and Diffuse C-MYC Staining Is Restricted to Hepatic Angiosarcoma. 2015, *Modern Pathology*, 28, Supplement, 416A.
19. Waterhouse EG, Joseph NM, Yilmaz F, Nart D, Evason KJ, Kim GE, Kakar S, Ferrell LD, **Gill RM**, Solomon DA. Validation of an RT-PCR Assay for Detection of Recurrent DNAJB1-PRKACA Fusion Transcripts in Fibrolamellar Hepatocellular Carcinoma. 2015, *Modern Pathology*, 28, Supplement, 425A.
20. Wang L, **Gill RM***, Ai W*. CD70 Expression in Mature T and NK Cell Neoplasms: A Potential Therapeutic Target. 2015, *Modern Pathology*, 28, Supplement, 384A.
* designates shared authorship
21. Hameed B, Terrault N, **Gill RM**, Loomba R, Chalasani N, Hoofnagle JH, Van Natta NL. Separate and Combined Effects of Obeticholic Acid and Weight Loss in Nonalcoholic Steatohepatitis. Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), International Liver Congress Annual Meeting, Vienna Austria, 2015, LB-4372
22. Ajmara V, Bass N, **Gill RM**, Perito E, Hameed B, Yates K, Loomba R, Diehl AM, Terrault N, Aouizerat B. Novel Plasma Biomarkers Associated with Severity of Liver Histology in Adults with Non-Alcoholic Fatty Liver Disease. AASLD 2015.
23. Hameed B, Terrault N, **Gill RM**, Loomba R, Chalasani NP, Hoofnagle JH, Van Natta ML. Clinical and Metabolic Effects Associated with Weight Loss and Obeticholic Acid in Non-Alcoholic Steatohepatitis (NASH). *Hepatology*, AASLD 2015.
24. Kleiner DE, Belt PH, Van Natta ML, Brunt EM, Behling CA, **Gill RM**, Guy CD, Neuschwander-Tetri BA, Sanyal AJ. Extending the Ballooning Score Beyond 2: A Proposal for a New Balloon. *Hepatology*, AASLD, 2015.
25. Li Y, Verkouw KC, Tabtabai S, Barrios^R, **Gill R**, Koo J, Marboe C, Rodriguez ER, Tan CD, De Marco T, Estep JD, Hanna M, Maurer MS, Patel J, Selby VN, Semigran MJ, Stone JR. Using Gastrointestinal Biopsy to Predict Outcome in Patients Evaluated for Cardiac Transplantation for Amyloidosis: A Report from the International Consortium on Cardiac Amyloidosis Transplantation (iCCAT). American Transplant Congress, 2015.

26. Roberts D, Kakar S, **Gill RM**. Liver Transplantation in the Setting of Hepatocellular Carcinoma. Role of Tumor Differentiation in Predicting the Risk of Recurrence. USCAP 2016
27. Choi WT, Wang D, Jen KY, **Gill RM**. Histologic and Clinical Outcomes after Transplantation of Donor Livers with Small Versus Large Droplet Macrovesicular Steatosis. USCAP 2016
28. Wen KW, **Gill RM**. Immature B-cells can be detected in a subset of Adult and Pediatric Liver Biopsies: A potential Pitfall in the Diagnosis of B-lymphoblastic Leukemia/Lymphoma. USCAP 2016
29. Kleiner DE, Brunt EM, Belt PH, Wilson L, Guy CD, Yeh MM, **Gill RM**, Kowdley KV, Tetri BA, Sanyal AJ. Diagnostic Pattern and Disease Activity Are Related To Disease Progression and Regression in Nonalcoholic Fatty Liver Disease HEPATOLOGY. 64: 19A. Oct 2016
30. Ajmera VH, Belt PH, Wilson L, **Gill RM**, Loomba R, Kleiner DE, Tetri BA, Terrault N. No Benefit from Modest Alcohol Use in Nonalcoholic Fatty Liver Disease (NAFLD). HEPATOLOGY. 64: 16A. Oct 2016 Author URL
31. Roberts D, Kakar S, **Gill RM**. A point based grading system for hepatocellular carcinoma shows improved inter observer agreement and better identifies histologic features associated with recurrent disease after liver transplantation. LABORATORY INVESTIGATION. 97: 422A. Feb 2017
32. Li Y, Prakash S, **Gill RM**. Clinicopathologic Features of Hepatic Lymphoma, a Large Retrospective Study. LABORATORY INVESTIGATION. 97. FEB 2017
33. Joseph NM, Brunt EM, Marginean C, Nalbantoglu I, Snover DC, Thung SN, Yeh MM, Ferrell L, **Gill RM**. Cancer gene sequencing of hepatic small vessel neoplasm (HSVN) and hepatic cavernous hemangioma. LABORATORY INVESTIGATION. 97. FEB 2017
34. Ajmer V, Delucchi K, Aouizerat B, Gill RM, Loomba R, Terrault N, for the NASH CRN. Latent Class Analysis Reveals Distinct Classes of NAFLD. HEPATOLOGY. submitted
35. Kleiner DE, Sanyal AJ, Belt PH, Wilson L, Allende DS, Brunt EM, Contos MJ, Cummings O, **Gill RM**, Guy CD, Lai J, Yeh MW, Behling CA. Associations of the Grade and Relative Dominance of Perisinusoidal versus Portal Fibrosis In Nonalcoholic Fatty Liver Disease (NAFLD). HEPATOLOGY. October 2017
36. Kleiner DE, Sanyal AJ, Belt PH, Wilson L, Allende DS, Brunt EM, Carpenter D, Contos MJ, Cummings O, **Gill RM**, Guy CD, Yeh M, Behling CA. Patterns of Fibrosis Progression and Regression in Steatohepatitis. NASH Clinical Research Network. USCAP 2018
37. Choi WT, Wen KW, Rabinovitch PS, Huang D, Mattis AN, **Gill RM**. DNA Flow Cytometric Analysis and Outcomes of Serrated Lesions in Inflammatory Bowel Disease. USCAP 2018
38. Fels Elliott R, Ferrell L, Hameed B, Kakar S, **Gill RM**. Parenchymal Rejection in Liver Transplant Biopsies: A Form of Rejection Distinct from Severe Acute Cellular Rejection. USCAP 2018
39. Joseph NM, Brunt E, Marginean EC, Nalbantoglu I, Thung S, Yeh MM, Umetsu SE, Ferrell LD, Snover DC, and **Gill RM**. Recurrent GNAQ and GNA14 mutations in hepatic small vessel neoplasms. USCAP 2018
40. Robert D, Kakar S, and **Gill RM**. P53 immunohistochemistry in hepatocellular carcinoma correlates with recurrent disease following liver transplantation. USCAP 2018
41. Balitzer D , Tsai, JH, and **Gill RM**. Comparison of clinicopathologic features between recurrent and de novo post-transplant non-alcoholic steatohepatitis. USCAP 2018

42. Wen KW, Umetsu SE, Goldblum JR, **Gill RM**, Kim GE, Joseph NM, Rabinovitch PS, Kakar S, Lauwers GY, Choi W-T. DNA Flow Cytometric and Interobserver Study of “Crypt Cell Atypia” in Inflammatory Bowel Disease. *Modern Pathology*, 2019.
43. Fels-Elliott DR, Tavakol M, Hameed B, Ferrell LD, Kakar S, **Gill RM**. Evaluation of Clinicopathologic Presentation and Outcomes in Parenchymal Rejection Versus Acute Cellular Rejection in Liver Transplant Biopsies. *Modern Pathology*, 2019.
44. Blank A, Joseph NM, **Gill RM**, Kakar S. LFABP-Negative Hepatocellular Adenoma: Spectrum of Morphologic and Molecular Characteristics with Emphasis on Atypical Features. *Modern Pathology*, 2019.
45. Balitzer D, Saunders TA, Molden B, Kakar S, **Gill RM**. BRAF V600E and BAP1 immunohistochemistry aids in distinction between bile duct adenoma and intrahepatic cholangiocarcinoma. *Modern Pathology*, 2019.
46. Behling C, Guy CD, Allende D, Yeh M, Cummings OW, **Gill RM**, Carpenter D, Belt PH, Mark Natta V, Contos MJ, Kleiner DE. Bile Ductular and Portal Pathology in Fatty Liver Disease. *Modern Pathology*, 2019.
47. Monika S, Yates, KP, Suzuki A, Lavine, JE, **Gill, RM**, Terrault, N, Dhindsa, S. LOW TESTOSTERONE IS ASSOCIATED WITH NASH AND FIBROSIS SEVERITY IN MEN WITH NAFLD. DDW 2019.
48. Wu C-H; **Gill RM**. Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models. ASH 2019.
49. Sarkar M, et al. Testosterone is a Key Risk Factor for Nonalcoholic Steatohepatitis (NASH) and NASH Fibrosis in Young Pre-Menopausal Women with Fatty Liver. AASLD 2020
50. D.J. Rowan, D. Allende, A.M. Bellizzi, **R.M. Gill**, X. Liu, C.A. McKenzie, R.K. Moreira, T. Mounajjed, S. Said, M. Westerhoff, S.M. Jenkins, K.P. Batts, L. Burgart, L.W. Lamps, R. Graham. Interobserver Variability and Accuracy in the Diagnosis of Focal Nodular Hyperplasia and Effect of Glutamine Synthetase Immunohistochemistry. *Modern Pathology* 2020